Giuseppe Santabarbara, Medical Doctor of Oncology at the San Giuseppe Moscati National Hospital, shared a post on LinkedIn:
“No differences in terms of Overall Survival, no differences!
‘After a median follow-up of 7.7 years (IQR, 6.0-10.9) for disease-free surviving patients, 54 (38%) and 51 (36%) patients had died in the adjuvant chemotherapy and hepatectomy-alone arms, respectively.
OS did not significantly differ between the two arms in all randomly assigned patients (HR, 1.07 [95% CI, 0.73 to 1.57]; P = .736) or all eligible patients (HR, 1.16 [95% CI, 0.78 to 1.73]; P = .468;).'”
Title: Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603
Authors: Yukihide Kanemitsu, Yasuhiro Shimizu, Junki Mizusawa, Yoshitaka Inaba, Shunsuke Tsukamoto, Atsuo Takashima, Masayuki Ohue, Koji Komori, Akio Shiomi, Manabu Shiozawa, Yusuke Suwa, Takeshi Suto, Yusuke Kinugasa, Yasumasa Takii, Hiroyuki Bando, Takaya Kobatake, Masafumi Inomata, Yasuhiro Shimada, Hiroshi Katayama, Haruhiko Fukuda
Read the full article on Journal of Clinical Oncology.
Read about JCOG0603 Trial on OncoDaily.
